EGFR and non-small cell lung carcinoma: In addition, a trial is currently underway to compare efficacy of the third‐generation EGFR TKI osimertinib with first‐generation erlotinib/gefitinib as monotherapy in the first‐line setting of activating EGFR mutant advanced NSCLC 36.